ABS-201
Pharmaceutical compound
From Wikipedia, the free encyclopedia
ABS-201 is an AI-designed monoclonal antibody against the prolactin receptor (PRLR) currently in Phase 1/2a clinical trial[2][3][4] for the treatment of androgenic alopecia (pattern hair loss) and endometriosis.[1][5][6][7] It is taken by subcutaneous injection.[1][6] ABS-201 is a possible first-in-class drug with a novel mechanism of action in the potential treatment of hair loss.[8] ABS-201 is under development by Absci.[9][10]
- None
| Clinical data | |
|---|---|
| Other names | ABS201 |
| Routes of administration | Subcutaneous injection[1] |
| Drug class | Prolactin receptor monoclonal antibody |
| ATC code |
|
It is believed that ABS-201 works by activating dormant hair follicles and causing them to move from the telogen phase to the anagen phase.[6][7] In human ex vivo scalp model studies, ABS-201 stimulated hair regrowth, prolonged anagen phase, blocked catagen phase, inhibited telogen effluvium, and blocked hair from losing color.[11][12] ABS-201 has been found to produce robust hair regrowth as compared with minoxidil in mice and balding macaques.[6][7]
The clinical trial for ABS-201 is being overseen by prominent hair loss researcher Rodney Sinclair,[6] one of the principal investigators in minoxidil clinical trials.[13][14] The chemical structure of the drug does not yet appear to have been disclosed.[1]
See also
- List of investigational hair loss drugs
- BAY-1158061 (HMI-115)
- PP405 and ET-02 (RS-5441)